X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Arven Pharma selects GE Healthcare to improve Turkish and regional access to biopharmaceuticals

Yuvraj_pawp by Yuvraj_pawp
2nd February 2017
in Research & Development

Arven Pharmaceuticals, a Toksoz Group Company, has selected GE Healthcare’s FlexFactory manufacturing platform to expand production capacity at its facility in Kirklareli, Turkey.

With this expanded capacity, Arven will support local healthcare needs by bringing biopharmaceuticals to the Turkish and surrounding markets faster, whilst also opening up European markets through the FlexFactory’s proven track record in meeting global regulations and quality standards.

Already Europe’s seventh largest pharmaceutical market, Turkey plans to further grow and transform its healthcare sector, reaching 60% local production for its pharmaceutical medicines by 2023(1). Arven has opted to expand its production capacity in Turkey with GE’s FlexFactory platform which is based on integrated single-use technologies enabling flexible and efficient biomanufacturing operations. The resulting productivity improvements will support Arven’s biosimilars pipeline moving through the clinic to regulatory approval.


Irem Yenice, Ph.D., Head of Biotechnology and R&D Director, Arven Pharmaceuticals, said: “We used a range of different criteria to make our decision to employ single use systems for mammalian cell-based bioproduction. This included flexibility of systems, strength of local organization, technical support, speed, and collaborative work structure. GE Healthcare’s standards, and the FlexFactory platform, met our requirements. The project evaluation time was long enough to assess GE regarding our needs for biosimilar development and production. Recently, Turkey has been focusing on local production of biotechnological products. Therefore, we believe that business opportunities among the companies with similar goals in the industry will increase by utilizing single use technologies.”


Sven Henrichwark, General Manager, Global Commercial BioProcess, GE Healthcare Life Sciences, said: “Our new Fast Trak Service Center in Istanbul allows us to work closely with Arven, one of the country’s key biopharma companies, to help deliver increased capacity as well as supporting Turkey’s growing pharma industry requirements more rapidly. Turkey’s desire to boost local manufacturing capacity is an industry need we are hearing echoed across the globe. Local production capability is a crucial element in providing national healthcare systems with the vital medicines to address growing patient needs. We are excited to contribute to Arven’s development by delivering a robust and flexible biomanufacturing solution, that also includes final qualification and training.”


GE opened their Fast Trak Service Center in Istanbul in March 2016. Based in GE’s Turkey Innovation Center, the laboratory is well-located to support the region’s growing industry, and help position Turkey as a global research, development and manufacturing hub.


About FlexFactory

GE Healthcare’s FlexFactory is a centrally automated, flexible biomanufacturing platform. It allows manufacturers to quickly and easily establish biopharmaceutical manufacturing capacity within an existing building or as part of a new facility. FlexFactory is designed to help manufacturers such as Arven Pharmaceutical to rapidly respond to local healthcare needs and to support global customers in bringing lifesaving treatments to market more quickly, FlexFactory is primarily comprised of single-use technologies and associated process hardware and integrated with automation and control components for start-to-finish manufacturing of biopharmaceuticals.

About Fast Trak
GE’s Fast Trak Service Centers are specifically designed to help biopharmaceutical manufacturers increase their process productivity, reduce cost and enable them to bring their products to market faster. The centers are equipped with the latest technologies for bioprocessing in an environment and at a scale that closely replicates the real-life industrial setting. For over 30 years, thousands of customers world-wide have been trained by GE’s experienced Fast Trak leadership teams, giving customers access to industry expertise encompassing process and analytical development, process scale-up, as well as manufacture of drug substances for use in toxicology studies or Phase I and II clinical testing.

GE Healthcare has Fast Trak Service Centers in South Korea, the USA, Sweden, India, and China and satellite Fast Trak Centers in Turkey, Japan and Singapore. Worldwide, more than 500 customers attend standard Fast Trak courses every year, with training available in local languages. In addition, there are customized courses that are built upon request and tailored according to customer needs.

About Arven Pharmaceuticals
Arven; a 100% Turkish capitalized pharmaceutical company, founded in 2012, is an R&D based high-tech pharmaceutical company which focusing on research and development, manufacturing and marketing of high-tech pharmaceutical products, including mainly biotech drugs containing therapeutic proteins and multi-dose innovative devices for Dry Powder Inhalers. Arven succeeded in developing the first Turkish patented dry powder inhaler “Sanohaler®” as a result of long lasting R&D activities, which is a very important milestone in Turkish Pharmaceutical Industry.


Moreover, as a result of their investments in biotechnology, Arven Pharmaceuticals succeeded in authorising Turkey’s first biotechnological biosimilar product that was produced and developed by Turkish Pharmaceutical Industry.

Arven Pharmaceuticals Biotechnology Division continues its efforts towards improving public health with its qualified researchers and personnel, who have experience in biosimilar product development and hold advanced degrees, and its biosimilar product development infrastructure, which continues to grow each day. Toksöz Group steadily works on its largest investment in this area, which is a 28,000-square meter, high-tech product manufacturing facility for Arven Pharmaceuticals situated in the Kırklareli Industrial Zone. Arven’s vision is to develop high-tech products to the highest quality standards to achieve global recognition. For more information go to: www.arvenilac.com.tr

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com


Contact:
GE Healthcare
Saara Nordenström
Communications
T +46 7386 81286
E saara.nordenstrom@ge.com
 

Previous Post

Allergan Successfully Completes LifeCell Acquisition

Next Post

Allergan Launches See America , a Bold Initiative Furthering the Fight Against Preventable Blindness

Related Posts

Tumors Can Get Destroyed By Bacteria-Aid To Immune System
News

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

16th March 2023
News

Researchers Develop Revolutionary Treatment In Bone Cancer

10th March 2023
News

T Cells Are Fruitful In Thwarting-Off Chronic Infections

10th March 2023
News

Randomness Drives Tumour Cells Response To Chemotherapy

10th March 2023
Featured

Animal Testing Could See An End With An Artificial Model

28th February 2023
Featured

Germany Rolls First CAR-T Push For Muscle Inflammation Cure

27th February 2023
Next Post

Allergan Launches See America , a Bold Initiative Furthering the Fight Against Preventable Blindness

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In